Is immunotherapy a viable option in treating mesothelioma?

2017-08-01

Future Oncology , Volume 13 - Issue 20 p. 1747- 1750

Additional Metadata
Keywords	CAR T cells, CTLA4, dendritic cells, immunotherapy, M2 macrophages, mesothelioma, PD-1/PD-L1, tumor micro-environment
Persistent URL	doi.org/10.2217/fon-2017-0234, hdl.handle.net/1765/108710
Journal	Future Oncology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Dumoulin, D.W. (Daphne W), Aerts, J., & Cornelissen, R. (2017). Is immunotherapy a viable option in treating mesothelioma?. Future Oncology (Vol. 13, pp. 1747–1750). doi:10.2217/fon-2017-0234

Publication